Comparative pharmacokinetics of ceftazidime and moxalactam
- PMID: 6765416
- PMCID: PMC183718
- DOI: 10.1128/AAC.22.2.237
Comparative pharmacokinetics of ceftazidime and moxalactam
Abstract
The pharmacokinetics of ceftazidime and moxalactam were compared after intravenous and intramuscular administration of single 1-g doses to eight healthy volunteers in a crossover study. The bioavailability of the antibiotics after administration by either route was almost complete. Both drugs had similar areas under the serum curves. Significant differences between ceftazidime and moxalactam were observed with respect to the apparent volume of distribution (18.4 and 24.1 liters, respectively), to the terminal half-life (1.6 versus 2.0 h), and to urinary recovery of the active compound (96 versus 79%). Ceftazidime was almost completely eliminated by renal excretion (greater than 96%), whereas about 20% of the moxalactam was eliminated by nonrenal mechanisms. The concentrations of ceftazidime and moxalactam in serum after a 1-g dose exceeded the concentrations required to inhibit 90% of the Enterobacteriaceae for about 8 and 10 h, respectively. The levels of ceftazidime and moxalactam in serum exceeded the 90% minimal inhibitory concentration of Pseudomonas aeruginosa for about 6 and 1 h, respectively.
Similar articles
-
Pharmacokinetics of moxalactam in elderly subjects.Antimicrob Agents Chemother. 1984 Jan;25(1):33-6. doi: 10.1128/AAC.25.1.33. Antimicrob Agents Chemother. 1984. PMID: 6703682 Free PMC article.
-
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.Antimicrob Agents Chemother. 1984 Sep;26(3):388-93. doi: 10.1128/AAC.26.3.388. Antimicrob Agents Chemother. 1984. PMID: 6391372 Free PMC article.
-
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.Antimicrob Agents Chemother. 1981 Nov;20(5):567-75. doi: 10.1128/AAC.20.5.567. Antimicrob Agents Chemother. 1981. PMID: 6275776 Free PMC article. Clinical Trial.
-
Ceftazidime review.Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):509-13. doi: 10.1177/106002808501900701. Drug Intell Clin Pharm. 1985. PMID: 3896712 Review.
-
Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.Pharmacotherapy. 1985 Sep-Oct;5(5):254-67. doi: 10.1002/j.1875-9114.1985.tb03424.x. Pharmacotherapy. 1985. PMID: 3906585 Review.
Cited by
-
Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.Antimicrob Agents Chemother. 1997 Feb;41(2):401-9. doi: 10.1128/AAC.41.2.401. Antimicrob Agents Chemother. 1997. PMID: 9021198 Free PMC article.
-
Effect of decreased renal function on the pharmacokinetics of ceftazidime.Antimicrob Agents Chemother. 1984 Jun;25(6):785-6. doi: 10.1128/AAC.25.6.785. Antimicrob Agents Chemother. 1984. PMID: 6378087 Free PMC article.
-
An Application of a Physiologically Based Pharmacokinetic Approach to Predict Ceftazidime Pharmacokinetics in a Pregnant Population.Pharmaceutics. 2024 Mar 28;16(4):474. doi: 10.3390/pharmaceutics16040474. Pharmaceutics. 2024. PMID: 38675135 Free PMC article.
-
Clinical pharmacokinetics of the third generation cephalosporins.Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001. Clin Pharmacokinet. 1985. PMID: 3888488 Review.
-
Dosage adjustment for ceftazidime in patients with impaired renal function.Eur J Clin Pharmacol. 1986;30(5):597-605. doi: 10.1007/BF00542421. Eur J Clin Pharmacol. 1986. PMID: 3530782
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources